Targeting granzyme B with a novel inhibitor for the treatment of radiodermatitis

Radiodermatitis is a group of skin reactions that occur as a result of radiation therapy. It is a significant health challenge as approximately 70% of all cancer patients receive radiation therapy and approximately 95% of them experience radiodermatitis. Patients with radiodermatitis experience redness, itchiness, pain, scaling, and weeping or crusted wounds. Importantly, radiodermatitis can impede cancer treatments. Current treatments for radiodermatitis have shown limited efficacy; thus, improving our understanding of radiodermatitis and developing novel therapies are urgent needs. In our preliminary studies, we have found that the protein Granzyme B is present at very high levels in radiodermatitis skin. We also showed that Granzyme B damages components of the skin and promotes inflammation in radiodermatitis. Our proposed project will test if Granzyme B induces the symptoms of radiodermatitis and if our newly developed medication that stops Granzyme B activity can alleviate these symptoms. Findings from this study will provide further rationale to pursue inhibitors of Granzyme B as a novel treatment option for radiodermatitis.

Faculty Supervisor:

David Granville


Layla Nabai;Megan Pawluk;Christopher Turner


Vancouver General Hospital




Health care and social assistance


University of British Columbia



Current openings

Find the perfect opportunity to put your academic skills and knowledge into practice!

Find Projects